Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization - PubMed (original) (raw)

. 1998 Apr;177(4):1112-5.

doi: 10.1086/517407.

Affiliations

• PMID: 9534995
• DOI: 10.1086/517407

Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization

D Goldblatt et al. J Infect Dis. 1998 Apr.

Abstract

Evaluation of the new generation of conjugate vaccines is hampered by the absence of reliable surrogate markers of immunologic memory. Memory responses are characterized by rapid production of relatively high-avidity antibody; thus, a solid-phase ELISA was adapted for the measurement of anti-Haemophilus influenzae type b (Hib) IgG avidity. In a cohort of infants vaccinated at 2, 3, and 4 months of age with Hib conjugate vaccines, avidity increased in the period following vaccination, while antibody titer fell. After a booster dose at 1 year of age, both antibody titer and avidity increased. In a cohort with anti-Hib IgG <1.0 microg/mL following primary immunization, antibody avidity after booster was low, indicating an absence of priming. Antibody avidity may help distinguish, in persons with low antibody titers, between those who are primed for memory and those who are not.

PubMed Disclaimer

Similar articles

• Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody.
  Lee YC, Kelly DF, Yu LM, Slack MP, Booy R, Heath PT, Siegrist CA, Moxon RE, Pollard AJ. Lee YC, et al. Clin Infect Dis. 2008 Jan 15;46(2):186-92. doi: 10.1086/524668. Clin Infect Dis. 2008. PMID: 18171249
• Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants.
  Klein NP, Abu-Elyazeed R, Cornish M, Leonardi ML, Weiner LB, Silas PE, Grogg SE, Varman M, Frenck RW, Cheuvart B, Baine Y, Miller JM, Leyssen M, Mesaros N, Roy-Ghanta S. Klein NP, et al. Vaccine. 2017 Jun 16;35(28):3564-3574. doi: 10.1016/j.vaccine.2017.05.018. Epub 2017 May 20. Vaccine. 2017. PMID: 28536030 Clinical Trial.
• Impaired haemophilus influenzae type b transplacental antibody transmission and declining antibody avidity through the first year of life represent potential vulnerabilities for HIV-exposed but -uninfected infants.
  Gaensbauer JT, Rakhola JT, Onyango-Makumbi C, Mubiru M, Westcott JE, Krebs NF, Asturias EJ, Fowler MG, McFarland E, Janoff EN. Gaensbauer JT, et al. Clin Vaccine Immunol. 2014 Dec;21(12):1661-7. doi: 10.1128/CVI.00356-14. Epub 2014 Oct 8. Clin Vaccine Immunol. 2014. PMID: 25298109 Free PMC article.
• Assessing efficacy of Haemophilus influenzae type b combination vaccines.
  Granoff DM. Granoff DM. Clin Infect Dis. 2001 Dec 15;33 Suppl 4:S278-87. doi: 10.1086/322563. Clin Infect Dis. 2001. PMID: 11709760 Review.
• Circulating innate and adaptive immunity against anti-Haemophilus influenzae type b.
  Zarei AE, Linjawi MH, Redwan EM. Zarei AE, et al. Hum Antibodies. 2019;27(3):201-212. doi: 10.3233/HAB-190373. Hum Antibodies. 2019. PMID: 30958343 Review.

Cited by

• Differences in affinity of monoclonal and naturally acquired polyclonal antibodies against Plasmodium falciparum merozoite antigens.
  Reddy SB, Anders RF, Cross N, Mueller I, Senn N, Stanisic DI, Siba PM, Wahlgren M, Kironde F, Beeson JG, Persson KE. Reddy SB, et al. BMC Microbiol. 2015 Jul 3;15:133. doi: 10.1186/s12866-015-0461-1. BMC Microbiol. 2015. PMID: 26149471 Free PMC article.
• Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.
  Ekström N, Ahman H, Verho J, Jokinen J, Väkeväinen M, Kilpi T, Käyhty H. Ekström N, et al. Infect Immun. 2005 Jan;73(1):369-77. doi: 10.1128/IAI.73.1.369-377.2005. Infect Immun. 2005. PMID: 15618174 Free PMC article. Clinical Trial.
• Effect of a fourth Haemophilus influenzae type b immunisation in preterm infants who received dexamethasone for chronic lung disease.
  Clarke P, Powell PJ, Goldblatt D, Robinson MJ. Clarke P, et al. Arch Dis Child Fetal Neonatal Ed. 2003 Jan;88(1):F58-61. doi: 10.1136/fn.88.1.f58. Arch Dis Child Fetal Neonatal Ed. 2003. PMID: 12496229 Free PMC article.
• Chromogenic assay measuring opsonophagocytic killing capacities of antipneumococcal antisera.
  Lin JS, Park MK, Nahm MH. Lin JS, et al. Clin Diagn Lab Immunol. 2001 May;8(3):528-33. doi: 10.1128/CDLI.8.3.528-533.2001. Clin Diagn Lab Immunol. 2001. PMID: 11329452 Free PMC article.
• Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months.
  Russell FM, Balloch A, Licciardi PV, Carapetis JR, Tikoduadua L, Waqatakirewa L, Cheung YB, Mulholland EK, Tang ML. Russell FM, et al. Vaccine. 2011 Jun 15;29(27):4499-506. doi: 10.1016/j.vaccine.2011.04.038. Epub 2011 May 1. Vaccine. 2011. PMID: 21539882 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Medical

  • MedlinePlus Health Information